ARCHIVES

FDA Oncologic Drugs Advisory Committee: Trials In A Small Indication Tell Big Story About Pitfalls of Delaying Progression

This article is from The Cancer Letter archive.

Vol. 37 No. 15 | April 15, 2011

Download PDF Visit The Full Archive

Related Articles

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

February 17, 2012

Patient Advocacy: Policy Should Prevent Employers From Using Genetic Test Results

April 11, 1997

An Early Look At How NCI Plans To Spend Its Money In 1980

July 7, 1978

Children of Male Cancer Survivors Have Highrt Risk of Birth Defects

February 25, 2011

Improved NCI Relations With FDA Cited As Model For Government Accord, Lasagna Committee Says

April 20, 1990

ASCO Advises KRAS Testing In Patients With Metastatic Colorectal Cancer

January 30, 2009